The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
about
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
description
scientific article published on 10 October 2019
@en
name
The renal hemodynamic effects ...... omized, double-blind RED trial
@en
type
label
The renal hemodynamic effects ...... omized, double-blind RED trial
@en
prefLabel
The renal hemodynamic effects ...... omized, double-blind RED trial
@en
P2093
P1433
P1476
The renal hemodynamic effects ...... omized, double-blind RED trial
@en
P2093
A H Jan Danser
Andrea Bozovic
Anna L Emanuel
Daan J Touw
Daniël H van Raalte
Emil L Larsen
Erik J M van Bommel
Ewout J Hoorn
Frank Geurts
Henrik E Poulsen
P304
P356
10.1016/J.KINT.2019.09.013
P50
P577
2019-10-10T00:00:00Z